

FIRST AND ONLY GLP-1 RA indicated in combination with an SGLT2i^{1*}



Trulicity[®] AWARD-10 study

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

Demonstrated to improve glycemic control^{2*}

Trulicity is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with:

- diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance.
- metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.
- metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.
- sodium glucose co-transporter 2 inhibitor (SGLT2i) with metformin, when diet and exercise plus SGLT2i with or without metformin do not achieve adequate glycemic control.
- basal insulin with metformin, when diet and exercise plus basal insulin with or without metformin do not achieve adequate glycemic control.
- prandial insulin with metformin, when diet and exercise plus basal or basal-bolus insulin therapy (up to two injections of basal or basal plus prandial insulin per day) with or without oral antihyperglycemic medications, do not achieve adequate glycemic control.

GLP-1 RA=glucagon-like peptide-1 receptor agonist;
SGLT2i=sodium glucose co-transporter 2 inhibitor.

* Comparative clinical significance has not been established.

once weekly
trulicity[®]
(dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL

Leanne is working with her health care provider to lower her A1c*

Leanne

Hospital administrator

58 years old

Type 2 diabetes
diagnosed 9 years ago



Currently taking
metformin 1500 mg/day
empagliflozin 25 mg/day



A1c: 8.0% at
the past two visits



BMI: 32 kg/m²†



Exercises once or
twice a week

**Leanne is unsure about the next step
in her diabetes treatment.**

* Fictitious patient profile. May not be representative of all patients.
† Trulicity is not indicated for weight loss.

Help improve glycemic control in your patients on an SGLT2i with Trulicity²

In the AWARD-10 trial patients receiving Trulicity 1.5 mg
(+ SGLT2i ± metformin)

- Demonstrated mean A1c reduction of up to 1.3%
- 67% of patients achieved an A1c <7%

A ready-to-use pen^{2*}

- Start a therapeutic dose of 0.75 mg once weekly
- Shown to be easy to learn and easy to use
- Convenient, once-weekly dosing

Single dose,
ready-to-use pens

**Trulicity is the
FIRST AND ONLY**
GLP-1 RA indicated
in combination with
an SGLT2i^{1*}




* Comparative clinical significance has not been established.

Trulicity demonstrated superior A1c reduction vs. placebo

(both + SGLT2i ± metformin).^{2*}

A1c reduction from baseline at Week 24, intent-to-treat population



Adapted from Product Monograph.

Proportion of patients achieving A1c <7% at 24 weeks



Trulicity 1.5 mg + SGLT2i ± metformin

vs.



Placebo + SGLT2i ± metformin

² 24-week, phase 3, multicentre, randomized, parallel-arm, double-blind, placebo-controlled trial. Patients were randomized and received Trulicity 0.75 mg or 1.5 mg once weekly or placebo once weekly, all as add-on to an SGLT2i ± metformin.

● ● ●

Could Trulicity change the way Leanne thinks about starting a new treatment?²



START a therapeutic dose
of 0.75 mg once weekly



Can be taken
at any time of day,
independent of meals



Easy to learn and easy to use



Once-weekly dosing



Available in single-dose, ready-to-use pens^{2*}

- The dose is premixed and each pen contains one dose of Trulicity[†]
- Pre-attached, hidden needle
- Automatic dose delivery at the press of a button^{*}

Available in two doses

* Clinical significance has not been demonstrated.

† The pen is a disposable, pre-filled delivery device.
Each pen contains one weekly dose of Trulicity and
is for one-time use only.

Clinical use:

Trulicity is not a substitute for insulin. Trulicity should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Contraindications:

- Patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnant and nursing women

Most serious warnings and precautions:

Risk of thyroid C-cell tumors: In male and female rats, dulaglutide causes dose-dependent and treatment duration-dependent thyroid C-cell tumors after lifetime exposure. Patients should be counseled regarding the risk and symptoms of thyroid tumors.

Other relevant warnings and precautions:

- Heart rate increase
- Prolongation of PR interval
- Hypoglycemia (in combination with an insulin secretagogue or insulin)
- Severe gastrointestinal disease
- Pancreatitis
- Systemic hypersensitivity, including postmarketing reports of serious reactions (e.g., anaphylactic reactions and angioedema)
- Nausea, vomiting and diarrhea can lead to dehydration. It is important to avoid dehydration which can cause serious kidney problems even in people with normal kidney function
- Not studied in pediatric patients
- No dose adjustment required in patients over 65 years of age
- Hepatic or renal impairment
- Recent myocardial infarction, unstable angina and congestive heart failure

For more information:

Please consult the product monograph at www.lilly.ca/TrulicityPM/en for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The product monograph is also available by calling us at 1-888-545-5972.

References: **1.** Eli Lilly Canada Inc. Data on file. **2.** Trulicity Product Monograph. Eli Lilly Canada Inc. August 15, 2019. **3.** Ludvik B, *et al.* Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endo* 2018;6:370-81.

TRULICITY is a registered trademark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates. © 2020, Eli Lilly and Company. All rights reserved.



once weekly
trulicity[®]
(dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL